OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Chen, Aoshuang
Associate Professor of Immunology
eRA COMMONS USER NAME (credential, e.g., agency login)
CHENAO
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
Univ. of Cincinnati, Cincinnati, OH
Univ. of Cincinnati, Cincinnati, OH
Case Western Reserve Univ., Cleveland, OH
Ph.D.
Post Doc.
Post Doc.
1986-92
1992-93
1995-98
Molecular Biology
Cell Biology
Immunology
Please refer to the Biographical Sketch sample in order to complete sections A, B, C, and D of the
Biographical Sketch.
A. Positions and Honors
1999-2003
Instructor, Department of Pathology and Laboratory Medicine, University of Pennsylvania,
Philadelphia, PA
2003-2009
Assistant Professor, Department of Biomedical Sciences, College of Medicine-Rockford,
University of Illinois at Chicago, Rockford, IL
2009-present
Associate Professor (with tenure), Department of Biomedical Sciences, College of
Medicine-Rockford, University of Illinois at Chicago, Rockford, IL
B. Selected Peer-reviewed Publications
1.
Chen A, Zheng G, and Tykocinski ML. Hierarchical costimulator thresholds for distinct immune
responses: Application of a novel two-step Fc fusion protein transfer method. J. Immunol., 164:705711, 2000.
2.
Rachmilewitz J, Huang J-H, Chen A, and Tykocinski ML. A rheostatic mechanism for T cell inhibition
based on elevation of activation thresholds. Blood, 98:3727-32, 2001.
3.
Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N, and Tykocinski ML. Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res., 61:8127-34, 2001.
4.
Chen A, Zheng G, and Tykocinski ML. Quantitative balance between activating and pro-apoptotic
signals dictates T cell responses. Cell. Immunol, 221:128-37, 2003.
5.
Zheng G, Wang B, and Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+
regulatory T cells. J. Immunol., 173: 2428-34, 2004.
6.
Chen A*, Xu H, Choi Y, Wang B, and Zheng G*. TRANCE counteracts FasL-mediated apoptosis of
murine bone marrow-derived dendritic cells. Cell. Immunol., 231:40-8, 2004.
*Correspondence author
7.
Jin H, Kang Y, Zheng G, Xie Q, Xiao C, Zhang X, Yu Y, Zhu K, Zhao G, Zhang F, Chen A, and Wang
B. Induction of active immune suppression by co-immunization with DNA- and protein-based
vaccines. Virology, 337: 183-91, 2005.
8.
Zheng G, Liu S, Wang P, Xu Y, and Chen A. Arming tumor-reactive T cells with costimulator B7-1
enhances therapeutic efficacy of the T cells. Cancer Res., 66:6793-9, 2006.
9.
Liu S, Foster, B, Chen T, Zheng G, and Chen A. Modifying dendritic cells via protein transfer for
antitumor therapeutics. Clin. Cancer Res., 13:283-91, 2007.
10.
Chen A*, Liu S, Park D, Kang Y, and Zheng G*. Depleting intratumoral CD4+CD25+ regulatory T
cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer
Res., 67:1291-8, 2007.
*Correspondence author
11.
Liu S, Breiter DR, Zheng G, and Chen A. Enhanced antitumor responses elicited by combinatorial
protein transfer of chemotactic and costimulatory molecules. J. Immunol., 178:3301-6, 2007.
12.
Kang Y, Xu L, Wang B, Chen A*, and Zheng G*. Cutting Edge: Immunosuppressant as adjuvant for
tolerogenic immunization. J. Immunol., 180:5172-6, 2008.
*Correspondence author
13.
Munirathinam G, Thirugnanam S, Zheng G, Chen A, and Ramaswamy K. Gene silencing of
translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of
human prostate cancer cells. Int. J. Oncol., 34:1241-6, 2009.
14.
Munirathinam G, Thirugnanam S, Zheng G, Chen A, and Ramaswamy K. T-oligo induces apoptosis
in advanced prostate cancer cells. Oligonucleotides. 19:287-92, 2009.
15.
Kang Y, Zhao J, Liu Y, Chen A, Zheng G, Yu Y, Mi J, Zou Q, and Wang B. FK506 as an adjuvant of
tolerogenic DNA vaccination for the prevention of experimental autoimmune encephalomyelitis. J.
Gene Med., 11:1064-70, 2009.
16.
Kang Y, Chen A, Wang B, and Zheng G. Protein transfer enhances cellular immune responses to
DNA vaccination against SARS-CoV. Viral Immunol., 22:1-6, 2009.
17.
Shetty A, Thirugnanam S, Dakshinamoorthy G, Samykutty A, Zheng G, Chen A, Bosland M,
Kajdacsy-Bella A, and Munirathinam G. 18alpha-glycyrrhetinic acid (AGA) targets prostate cancer
cells by downregulating inflammation related genes. Int. J. Oncology, 2011.
18.
Kang Y, Zheng G, Chen A, Wang J, Hu Y, Li J, Zhang J, Gao W, Fu H, Xia G, and Wang B.
Tolerogenic DNA vaccine for prevention of autoimmune ovarian disease. Immunol. Invest. 41:249-60,
2012.
19.
Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland M, Kajdacsy-Balla A, and Munirathinam G.
Targeting Receptor for Advanced Glycation End products (RAGE) expression induces apoptosis and
inhibits prostate tumor growth. Biochem. Biophys. Res. Commun., 417:1133-8, 2012.
20.
Chou SH, Shetty AV, Geng Y, Xu L, Munirathinam G, Pipathsouk A, Tan I, Morris T, Wang B, Chen
A*, and Zheng G*. Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of
low systemic toxicity. Cancer Immunol. Immunother., 62:597-603, 2013
*Correspondence author
21.
Zheng G*, Zhong S, Geng Y, Munirathinam G, Cha I, Reardon C, Getz GS, van Rooijen N, Kang Y,
Wang B, and Chen A*. Dexamethasone promotes tolerance in vivo by enriching CD11c(lo)CD40(lo)
tolerogenic macrophages. Eur. J. Immunol. 43:219-27, 2013.
*Correspondence author
22.
Munirathinam G, Zheng G, Chen A, Bosland MC, and Kajdacsy-Balla A. HMGB1: A Promising
Therapeutic Target for Prostate Cancer. Prostate Cancer, 2013:157103, 2013.
23.
Samykutty A, Shetty AV, Dakshinamoorthy G, Bartik MM, Johnson GL, Webb B, Zheng G, Chen A,
and Munirathinam G. Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects
on Androgen Dependent and Androgen Independent Prostate Cancer Cells. PLoS One, 8:e65889,
2013.
24.
Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, Bosland MC,
Kajdacsy-Balla A, and Gnanasekar M. Vitamin k2, a naturally occurring menaquinone, exerts
therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells.
Evid. Based Complement Alternat. Med., 2013:287358, 2013.
25.
Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A,
Kalyanasundaram R, and Munirathinam G. HMGB1 in hormone-related cancer: a potential
therapeutic target. Horm. Cancer, 5:127-39, 2014.
26.
Chen A*, Geng Y, Ke H, Constant L, Yan Z, Pan Y, Lee P, Tan I, Williams K, George S,
Munirathinam G, Reardon CA, Getz GS, Wang B, and Zheng G*. Cutting Edge: Dexamethasone
potentiates the responses of both regulatory T cells and B-1 cells to antigen immunization in the
ApoE(-/-) mouse model of atherosclerosis. J. Immunol., 193:35-9, 2014.
*Correspondence author
C. Research Support
Ongoing research support
R21 HL106340
12/1/10 – 11/30/14 (with 2nd no-cost extension)
NIH/ NHLBI
$275,000 (total direct cost)
“Immunization against Atherosclerosis”
The main goals of this grant are to assess the anti-atherogenic efficacy of suppressed immunization (SI)
that uses Dex and HSP60-derived epitopes, and to determine the contribution of HSP60-specificic Treg
cells to the tolerogenic efficacy of SI.
Role: PI
Overlap with this grant: None
Completed research support
RO1 CA92243
07/01/02 – 6/30/08 (with 1 year no-cost extension)
NIH/NCI
$890,000 (total direct cost)
“Combinatorial Protein Transfer for Cancer Therapeutics”
The major goals of this grant are to deepen the understanding of the regulation of T cell activation and
dendritic cell longevity, and to optimize the intratumoral protein transfer for therapeutics in the L5178Y T
lymphoma model.
Role: PI